Here we report that pharmacological selectivity of SGLT2 inhibitors does not significantly correlate with risk of MACE, cardiovascular death, fatal and nonfatal MI, all-cause mortality, hospitalization for HF, or the renal composite outcome in patients with type 2 diabetes mellitus and high cardiovascular risk. Here, SLC5A2 is linked to type 2 diabetes mellitus.